| Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ... The American Journal of Human Genetics 72 (5), 1117-1130, 2003 | 4936 | 2003 |
| Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021 | 2876* | 2021 |
| Birth incidence and prevalence of tumor‐prone syndromes: estimates from a UK family genetic register service DG Evans, E Howard, C Giblin, T Clancy, H Spencer, SM Huson, F Lalloo American journal of medical genetics Part A 152 (2), 327-332, 2010 | 1097 | 2010 |
| Revised guidelines for the clinical management of Lynch syndrome (HNPCC): recommendations by a group of European experts HFA Vasen, I Blanco, K Aktan-Collan, JP Gopie, A Alonso, S Aretz, ... Gut 62 (6), 812-823, 2013 | 894 | 2013 |
| Prediction of BRCA1 Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype SR Lakhani, JS Reis-Filho, L Fulford, F Penault-Llorca, M van der Vijver, ... Clinical cancer research 11 (14), 5175-5180, 2005 | 836 | 2005 |
| The BOADICEA model of genetic susceptibility to breast and ovarian cancers: updates and extensions AC Antoniou, AP Cunningham, J Peto, DG Evans, F Lalloo, SA Narod, ... British journal of cancer 98 (8), 1457-1466, 2008 | 650 | 2008 |
| RECOVERY Collaborative Group Dexamethasone in hospitalized patients with Covid-19 P Horby, WS Lim, JR Emberson, M Mafham, JL Bell, L Linsell, N Staplin, ... N Engl J Med 384 (8), 693-704, 2021 | 638* | 2021 |
| Germline mutations in RAD51D confer susceptibility to ovarian cancer C Loveday, C Turnbull, E Ramsay, D Hughes, E Ruark, JR Frankum, ... Nature genetics 43 (9), 879-882, 2011 | 638 | 2011 |
| Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database M Dominguez-Valentin, JR Sampson, TT Seppälä, SW Ten Broeke, ... Genetics in Medicine 22 (1), 15-25, 2020 | 624 | 2020 |
| Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database P Møller, TT Seppälä, I Bernstein, E Holinski-Feder, P Sala, DG Evans, ... Gut 67 (7), 1306-1316, 2018 | 624 | 2018 |
| Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database P Møller, T Seppälä, I Bernstein, E Holinski-Feder, P Sala, DG Evans, ... Gut 66 (3), 464-472, 2017 | 605 | 2017 |
| Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD CJ Ricketts, JR Forman, E Rattenberry, N Bradshaw, F Lalloo, L Izatt, ... Human mutation 31 (1), 41-51, 2010 | 426 | 2010 |
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 421 | 2017 |
| Guidelines for the management of hereditary colorectal cancer from the British Society of Gastroenterology (BSG)/Association of Coloproctology of Great Britain and Ireland … KJ Monahan, N Bradshaw, S Dolwani, B Desouza, MG Dunlop, JE East, ... Gut 69 (3), 411-444, 2020 | 418 | 2020 |
| Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations E Barrow, L Robinson, W Alduaij, A Shenton, T Clancy, F Lalloo, J Hill, ... Clinical genetics 75 (2), 141-149, 2009 | 415 | 2009 |
| Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme E Amir, DG Evans, A Shenton, F Lalloo, A Moran, C Boggis, M Wilson, ... Journal of medical genetics 40 (11), 807-814, 2003 | 399 | 2003 |
| Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations A Moran, C O’hara, S Khan, L Shack, E Woodward, ER Maher, F Lalloo, ... Familial cancer 11, 235-242, 2012 | 386 | 2012 |
| Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers KB Kuchenbaecker, L McGuffog, D Barrowdale, A Lee, P Soucy, J Dennis, ... JNCI: Journal of the National Cancer Institute 109 (7), djw302, 2017 | 357 | 2017 |
| Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ... PLoS genetics 9 (3), e1003212, 2013 | 351 | 2013 |
| A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO DGR Evans, DM Eccles, N Rahman, K Young, M Bulman, E Amir, ... Journal of medical genetics 41 (6), 474-480, 2004 | 333 | 2004 |
Evans DG*, Evans G*University of ManchesterEmail yang diverifikasi di mft.nhs.uk
